Teva Canada launches new Autoinjector for Ajovy to prevent migraine in adults

Teva Canada is offering a new autoinjector for Ajovy to prevent migraines in adults.

Ajovy now offers patients greater flexibility with two dosing options available in both an autoinjector and a prefilled syringe.  It is the first and only subcutaneous anti-CGRP treatment with both quarterly (every three months) and monthly dosing options using either the autoinjector or prefilled syringe for the preventive treatment of migraine in adults.

Ajovy is supported by theAjovy Teva Support Solutions Patient Support Program, whose services include reimbursement navigation, bridging/copay coverage, and injection training.

Ajovy has been studied in patients with either chronic or episodic migraine and was shown to significantly reduce patients’ mean monthly migraine days—with some patients achieving a 50% reduction or more.